Nitroxoline-O-protected derivatives inhibit MetAP2 and activate ATF4 through mTORC1 to inhibit cancer cell growth
Michael J. Williams, Conor T. Ronayne, Tanner J. Schumacher, Kayla M. Johnson, Matthew D. Wittmer, Johnson, Joseph L., Jr., Grant W. Anderson, Venkatram R. Mereddy
The paper synthesizes nitroxoline analogs that inhibit MetAP2 and activate ATF4 via mTORC1, showing anti-cancer effects in vitro.
Bioorganic & Medicinal Chemistry Letters · Mar 28, 2026Peer-reviewedCancer Biology